DK0991660T3 - Deuterede og udeuterede cyclosporinanaloger og deres anvendelse som immunmodulerende midler - Google Patents

Deuterede og udeuterede cyclosporinanaloger og deres anvendelse som immunmodulerende midler

Info

Publication number: DK0991660T3
Authority: DK; Denmark
Prior art keywords: cyclosporine; substitution; disclosed; derivatives; unutilized
Prior art date: 1997-10-08

Application number

DK98947718T

Other languages

Danish (da)

English (en)

Inventor

Randall W Yatscoff

Robert T Foster

S Selvaraj Naicker

Original Assignee

Isotechnika Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-08

Filing date

1998-10-08

Publication date

2006-02-13

1998-10-08 Application filed by Isotechnika Inc filed Critical Isotechnika Inc

2006-02-13 Application granted granted Critical

2006-02-13 Publication of DK0991660T3 publication Critical patent/DK0991660T3/da

Links

PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title abstract 9
230000002519 immonomodulatory effect Effects 0.000 title 1
238000006467 substitution reaction Methods 0.000 abstract 4
229930105110 Cyclosporin A Natural products 0.000 abstract 3
108010036949 Cyclosporine Proteins 0.000 abstract 3
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 2
229910052805 deuterium Inorganic materials 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
239000000126 substance Substances 0.000 abstract 2
230000001988 toxicity Effects 0.000 abstract 2
231100000419 toxicity Toxicity 0.000 abstract 2
108010036941 Cyclosporins Proteins 0.000 abstract 1
206010062016 Immunosuppression Diseases 0.000 abstract 1
125000003275 alpha amino acid group Chemical class 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
229930182912 cyclosporin Natural products 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
230000000155 isotopic effect Effects 0.000 abstract 1
230000004060 metabolic process Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Analytical Chemistry (AREA)
Diabetes (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Transplantation (AREA)
Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

DK98947718T 1997-10-08 1998-10-08 Deuterede og udeuterede cyclosporinanaloger og deres anvendelse som immunmodulerende midler DK0991660T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US6136097P	1997-10-08	1997-10-08

Publications (1)

Publication Number	Publication Date
DK0991660T3 true DK0991660T3 (da)	2006-02-13

Family

ID=22035297

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK98947718T DK0991660T3 (da)	1997-10-08	1998-10-08	Deuterede og udeuterede cyclosporinanaloger og deres anvendelse som immunmodulerende midler

Country Status (14)

Country	Link
US (3)	US6613739B1 (fr)
EP (1)	EP0991660B8 (fr)
JP (6)	JP4261049B2 (fr)
KR (1)	KR100585348B1 (fr)
AT (2)	ATE314388T1 (fr)
AU (1)	AU750245B2 (fr)
BR (1)	BR9811716A (fr)
CA (1)	CA2298572C (fr)
DE (2)	DE69840586D1 (fr)
DK (1)	DK0991660T3 (fr)
ES (1)	ES2256959T3 (fr)
NO (1)	NO324042B1 (fr)
NZ (1)	NZ502362A (fr)
WO (1)	WO1999018120A1 (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030220234A1 (en)	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
US20030119029A1 (en) *	1999-04-30	2003-06-26	Regents Of The University Of Michigan	Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20040176358A1 (en) *	1999-04-30	2004-09-09	The Regents Of The University Of Michigan	Compositions and methods relating to novel compounds and targets thereof
US7572788B2 (en)	1999-04-30	2009-08-11	The Regents Of The University Of Michigan	Compositions and methods relating to novel compounds and targets thereof
US20050113460A1 (en) *	1999-04-30	2005-05-26	The Regents Of The University Of Michigan	Compositions and methods relating to novel compounds and targets thereof
DE60042425D1 (de)	1999-04-30	2009-07-30	Univ Michigan	Verwendung von Benzodiazepinen zur Behandlung von autoimmunischen Krankheiten, Entzündungen, Neoplasien, viralen Infektionen und Atherosklerosis
US20060025388A1 (en)	1999-04-30	2006-02-02	Glick Gary D	Compositions and methods relating to novel compounds and targets thereof
US6784156B2 (en)	2001-03-05	2004-08-31	Enanta Pharmaceuticals, Inc.	Cyclosporins for the treatment of respiratory diseases
US6809077B2 (en)	2001-10-12	2004-10-26	Enanta Pharmaceuticals, Inc.	Cyclosporin analogs for the treatment of autoimmune diseases
US20030087813A1 (en)	2001-10-12	2003-05-08	Or Yat Sun	Cyclosporin analogs for the treatment of lung diseases
WO2003032949A1 (fr) *	2001-10-19	2003-04-24	Isotechnika Inc.	Nouveaux preconcentres en microemulsion d'analogues de cyclosporine
CA2460685C (fr) *	2001-10-19	2014-05-27	Isotechnika Inc.	Melanges d'analogues de cyclosporine et leur utilisation comme agents immunomodulateurs
DE60231570D1 (de)	2001-10-19	2009-04-23	Isotechnika Inc	Synthese von Cyclosporinanalogen
US20040110666A1 (en) *	2002-12-04	2004-06-10	Or Yat Sun	Cyclosporins for the treatment of immune disorders
DE10261807A1 (de) *	2002-12-19	2004-07-01	Turicum Drug Development Ag	Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
US7012065B2 (en)	2003-02-07	2006-03-14	Enanta Pharmaceuticals, Inc.	Cyclosporins for the treatment of immune disorders
US7538084B2 (en)	2003-03-17	2009-05-26	Amr Technology, Inc.	Cyclosporins
TW200505946A (en) *	2003-04-08	2005-02-16	Hoffmann La Roche	Process for preparation of cyclosporin a analog
US20040266669A1 (en) *	2003-06-20	2004-12-30	Wu Frank X. H.	Cyclosporin derivatives for the treatment of immune disorders
TW200517114A (en)	2003-10-15	2005-06-01	Combinatorx Inc	Methods and reagents for the treatment of immunoinflammatory disorders
WO2005094897A2 (fr) *	2004-04-01	2005-10-13	Cardiome Pharma Corp.	Derives de composes de modulation des canaux ioniques, compositions pharmaceutiques et utilisations
US7705036B2 (en) *	2004-04-01	2010-04-27	Cardiome Pharma Corp.	Deuterated aminocyclohexyl ether compounds and processes for preparing same
US20050272723A1 (en) *	2004-04-27	2005-12-08	The Regents Of The University Of Michigan	Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20090275099A1 (en) *	2004-04-27	2009-11-05	Regents Of The University Of Michigan	Methods and compositions for treating diseases and conditions associated with mitochondrial function
AU2005326322B2 (en) *	2004-07-01	2009-02-05	Yale University	Targeted and high density drug loaded polymeric materials
US20060014677A1 (en) *	2004-07-19	2006-01-19	Isotechnika International Inc.	Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
CA2575280C (fr) *	2004-07-29	2012-08-14	Amr Technology, Inc.	Nouveaux procedes de synthese stereoselective d'un compose isa<sb>tx</sb>247 trans
US20060052369A1 (en) *	2004-09-07	2006-03-09	The Regents Of The University Of Michigan	Compositions and methods relating to novel compounds and targets thereof
US7511013B2 (en)	2004-09-29	2009-03-31	Amr Technology, Inc.	Cyclosporin analogues and their pharmaceutical uses
US7378391B2 (en)	2004-09-29	2008-05-27	Amr Technology, Inc.	Cyclosporin alkyne analogues and their pharmaceutical uses
EP1812037A4 (fr)	2004-10-06	2009-11-11	Amr Technology Inc	Alcynes de cyclosporine, et leur utilite comme agents pharmaceutiques
CA2586925C (fr)	2004-11-18	2016-06-07	Cardiome Pharma Corp.	Processus de preparation par synthese de composes d'aminocyclohexyle ether
CA2592343A1 (fr) *	2004-12-17	2006-06-22	Isotechnika Inc.	Metabolites d'analogues de la cyclosporine
WO2006074358A1 (fr) *	2005-01-03	2006-07-13	The Regents Of The University Of Michigan	Compositions et procedes concernant de nouveaux composes et leurs cibles
DE602006012033D1 (de) *	2005-04-06	2010-03-18	Abbott Lab	Verfahren zur messung immunsuppressiver tacrolimus-, sirolimus- und cyclosporin-a-komplexe in einer blutprobe
AU2006309291B2 (en)	2005-06-01	2010-05-27	The Regents Of The University Of Michigan	Unsolvated benzodiazepine compositions and methods
JP5159616B2 (ja)	2005-06-15	2013-03-06	カーディオムファーマコーポレイション	アミノシクロヘキシルエーテル化合物の調製のための合成プロセス
AU2006299424A1 (en) *	2005-10-06	2007-04-12	Auspex Pharmaceuticals, Inc.	Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
US20070105844A1 (en) *	2005-10-26	2007-05-10	Regents Of The University Of Michigan	Therapeutic compositions and methods
EP2604269B1 (fr)	2005-11-01	2014-09-24	The Regents Of The University Of Michigan	1,4-benzodiazepine-2,5-diones possédant des propriétés thérapeutiques
CA2628570A1 (fr)	2005-11-09	2007-05-18	Combinatorx, Incorporated	Procedes, compositions et kits pour le traitement de pathologies
DK1954669T3 (en)	2005-12-01	2015-10-12	Auspex Pharmaceuticals Inc	SUBSTITUTED phenethylamines a serotonergic AND / OR NOREPINEPHRINERG ACTIVITY
GB0604647D0 (en)	2006-03-08	2006-04-19	Shchepinov Mikhail	Stabilized food supplements and their derivatives
US7696166B2 (en) *	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) *	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7759338B2 (en) *	2006-04-27	2010-07-20	The Regents Of The University Of Michigan	Soluble 1,4 benzodiazepine compounds and stable salts thereof
US8155649B2 (en) *	2006-05-12	2012-04-10	Shared Spectrum Company	Method and system for classifying communication signals in a dynamic spectrum access system
US8097612B2 (en)	2006-06-09	2012-01-17	The Regents Of The University Of Michigan	Compositions and methods relating to novel compounds and targets thereof
US10265407B2 (en)	2007-02-15	2019-04-23	Yale University	Modular nanodevices for smart adaptable vaccines
US20100151436A1 (en) *	2007-03-02	2010-06-17	Fong Peter M	Methods for Ex Vivo Administration of Drugs to Grafts Using Polymeric Nanoparticles
NZ579507A (en) *	2007-03-09	2011-11-25	Univ Michigan	Compositions and methods relating to novel compounds and targets thereof
ES2716048T3 (es)	2007-03-15	2019-06-07	Auspex Pharmaceuticals Inc	Fenetilamina sustituida con actividad serotoninérgica y/o norepinefrinérgica
US20100297666A1 (en) *	2007-08-01	2010-11-25	Gooch Jennifer L	Methods for determination of protein phosphatase activity, and uses in predicting therapeutic outcomes
EP2200977B1 (fr)	2007-09-14	2016-11-09	The Regents of the University of Michigan	Inhibiteur de f1f0-atpase et procédés associés
US8188072B2 (en)	2007-11-06	2012-05-29	The Regents Of The University Of Michigan	Benzodiazepinone compounds useful in the treatment of skin conditions
CA2715036A1 (fr)	2008-03-14	2009-09-17	Retrotope, Inc.	Therapies contre le cancer utilisant de la lysine substituee isotopiquement
BRPI0916769A2 (pt) *	2008-07-15	2017-09-26	Theracos Inc	derivados de benzilbenzeno deuterados e métodos de uso
CN102164948A (zh) *	2008-07-30	2011-08-24	伊索技术制药公司	非免疫抑制的环孢菌素类似分子
WO2010027448A1 (fr) *	2008-09-02	2010-03-11	Actimis Pharmaceuticals Inc.	Dérivés d'acide pyrimidin-5-ylacétique enrichis en isotopes en tant qu'antagonistes de crth2
CA2736091A1 (fr) *	2008-09-03	2010-03-11	Teva Pharmaceutical Industries Ltd.	Modulateurs 2-oxo-1,2-dihydro-quinoleines de la fonction immunitaire
EP2352724B1 (fr)	2008-09-11	2015-04-22	The Regents of the University of Michigan	Aryle guanidines comme inhibiteurs de la f1f0-atpase et leur utilisation medicale
BRPI0919920A2 (pt) *	2008-10-22	2016-02-16	Acucela Inc	compostos para tratamento de doenças e desordens oftálmicas
SG173180A1 (en)	2009-01-30	2011-09-29	Enanta Pharm Inc	Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en)	2009-02-19	2013-07-09	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8604023B2 (en)	2009-04-17	2013-12-10	The Regents Of The University Of Michigan	1,4-benzodiazepinone compounds and their use in treating cancer
US8349312B2 (en)	2009-07-09	2013-01-08	Enanta Pharmaceuticals, Inc.	Proline substituted cyclosporin analogues
US8685917B2 (en)	2009-07-09	2014-04-01	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8367053B2 (en)	2009-07-09	2013-02-05	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
WO2011035124A1 (fr)	2009-09-18	2011-03-24	The Regents Of The University Of Michigan	Composés de benzodiazépinone et méthodes de traitement les utilisant
EP2493296B1 (fr)	2009-10-30	2019-01-09	Retrotope, Inc.	Soulagement de troubles liés au stress oxydatif par des dérivés de pufa
CA2780287C (fr)	2009-11-17	2015-03-17	The Regents Of The University Of Michigan	1,4-benzodiazepine-2,5-diones et composes apparentes presentant des proprietes therapeutiques
AU2010322286B2 (en)	2009-11-17	2014-06-05	The Regents Of The University Of Michigan	1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US20110130711A1 (en) *	2009-11-19	2011-06-02	Follica, Inc.	Hair growth treatment
UY33226A (es) *	2010-02-19	2011-09-30	Novartis Ag	Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
US8623814B2 (en)	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
AU2011342284C1 (en)	2010-12-15	2017-07-13	Contravir Pharmaceuticals, Inc.	Cyclosporine analogue molecules modified at amino acid 1 and 3
WO2012145426A1 (fr)	2011-04-18	2012-10-26	The Trustees Of Columbia University In The City Of New York	Procédés pour traiter un cancer utilisant la cyclosporine et des dérivés de cyclosporine
AU2012249917B2 (en)	2011-04-26	2017-06-15	Biojiva Llc	Neurodegenerative disorders and muscle diseases implicating PUFAs
EP3730135A1 (fr)	2011-04-26	2020-10-28	Retrotope, Inc.	Troubles de traitement compromis de l'énergie et déficiences mitochondriales
WO2012148930A2 (fr)	2011-04-26	2012-11-01	Retrotope, Inc.	Rétinopathies oxydatives
KR102110175B1 (ko)	2011-04-26	2020-05-13	레트로토프 인코포레이티드	Ｐｕｆａ 산화와 관련된 장애
DE102011111991A1 (de)	2011-08-30	2013-02-28	Lead Discovery Center Gmbh	Neue Cyclosporin-Derivate
WO2013074650A1 (fr)	2011-11-18	2013-05-23	Codexis, Inc.	Biocatalyseurs pour la préparation de carbamates hydroxy substitués
EP2841098A4 (fr)	2012-04-23	2016-03-02	Allertein Therapeutics Llc	Nanoparticules pour le traitement d'allergies
US8906853B2 (en)	2012-11-28	2014-12-09	Enanta Pharmaceuticals, Inc.	[N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
EP3760223A1 (fr)	2013-04-03	2021-01-06	N-Fold Llc	Nouvelles compositions de nanoparticules
AU2014311346A1 (en)	2013-08-26	2016-03-17	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues for preventing or treating hepatitis C
EP3094314B1 (fr)	2014-01-16	2021-06-23	MUSC Foundation For Research Development	Nanosupports ciblés pour l'administration d'agents immunosuppresseurs
WO2016073480A1 (fr)	2014-11-03	2016-05-12	Enanta Pharmaceuticals, Inc.	Analogues de cyclosporine pour prévenir ou traiter une infection par l'hépatite c
US10730821B2 (en)	2015-11-23	2020-08-04	Retrotope, Inc.	Site-specific isotopic labeling of 1,4-diene systems
WO2018106928A1 (fr)	2016-12-08	2018-06-14	Contravir Pharmaceuticals, Inc.	Traitement et prévention de maladies du vhb par des molécules analogues de cyclosporine modifiées au niveau des acides aminés 1 et 3
AU2019206652B2 (en) *	2018-01-12	2024-11-14	Enb Therapeutics, Inc.	Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
WO2020082061A1 (fr)	2018-10-19	2020-04-23	Teva Pharmaceuticals International Gmbh	Formes à l'état solide de la voclosporine
JP2023514711A (ja)	2020-02-21	2023-04-07	レトロトップ、インコーポレイテッド	多価不飽和脂肪酸及びその誘導体の同位体修飾方法
CA3172601A1 (fr) *	2020-03-26	2021-09-30	Ching-Pong Mak	Preparation de derives de cyclosporine
US12109194B2 (en)	2021-02-05	2024-10-08	Biojiva Llc	Synergistic combination therapy for treating ALS
EP4201952A1 (fr)	2021-12-21	2023-06-28	Curia Spain, S.A.U.	Procédé de synthèse contrôlée de voclosporine
IT202300001116A1 (it) *	2023-01-25	2024-07-25	Indena Spa	Processo per la preparazione di un intermedio utile per la sintesi di voclosporina
WO2025119925A1 (fr)	2023-12-05	2025-06-12	Medichem, S.A.	Procédé de préparation de voclosporine

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4210581A (en)	1975-11-04	1980-07-01	Sandoz Ltd.	Organic compounds
CH614931A5 (fr)	1975-11-04	1979-12-28	Sandoz Ag
US4117118A (en)	1976-04-09	1978-09-26	Sandoz Ltd.	Organic compounds
DE2819094A1 (de)	1977-05-10	1978-11-23	Sandoz Ag	Cyclosporin-derivate, ihre verwendung und herstellung
SE448386B (sv)	1978-10-18	1987-02-16	Sandoz Ag	Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
US4201771A (en)	1979-03-12	1980-05-06	Merck & Co., Inc.	Antibiotic A43F
EP0098457B1 (fr)	1980-02-14	1987-08-05	Sandoz Ag	(1S,2R,3R)-et (1R,2S,3S)-Nitrilo-1-carbonyl-3-méthyl-2-oxy-heptanes et-hept-5-ènes utiles dans la synthèse totale de cyclosporines et procédé pour leur préparation
US4396542A (en)	1980-02-14	1983-08-02	Sandoz Ltd.	Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
FR2487198A1 (fr)	1980-07-28	1982-01-29	Berri Balzac Sa	Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique
US4384996A (en)	1981-01-09	1983-05-24	Sandoz Ltd.	Novel cyclosporins
CH667274A5 (de)	1984-03-23	1988-09-30	Sandoz Ag	Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
US4727018A (en)	1984-05-18	1988-02-23	Eichner Ronald D	Immunoregulation of transplantable tissue
US5639724A (en)	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
GB8422253D0 (en)	1984-09-04	1984-10-10	Sandoz Ltd	Organic compounds
EP0194972B1 (fr)	1985-03-11	1992-07-29	Sandoz Ag	Cyclosporines
US4765980A (en)	1986-04-28	1988-08-23	International Minerals & Chemical Corp.	Stabilized porcine growth hormone
US4764503A (en)	1986-11-19	1988-08-16	Sandoz Ltd.	Novel cyclosporins
NL194638C (nl)	1986-12-19	2002-10-04	Novartis Ag	Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.
US5427960A (en)	1987-03-27	1995-06-27	Abbott Laboratories	Fluorescence polarization assay for cyclosporin A and metabolites and related immunogens and antibodies
EP0283801A3 (fr) *	1987-03-27	1990-05-30	Abbott Laboratories	Essais de polarisation par fluorescence pour cyclosporine A et les métabolites et immunogènes et anticorps apparentés
US5239057A (en)	1987-03-27	1993-08-24	Abbott Laboratories	Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
US4798823A (en)	1987-06-03	1989-01-17	Merck & Co., Inc.	New cyclosporin analogs with modified "C-9 amino acids"
US4885276A (en)	1987-06-03	1989-12-05	Merck & Co., Inc.	Cyclosporin analogs with modified "C-9 amino acids"
JP2577049B2 (ja)	1987-06-04	1997-01-29	三共株式会社	シクロスポリン製剤
ES2059558T3 (es) *	1987-06-17	1994-11-16	Sandoz Ag	Ciclosporins y su uso como productos farmaceuticos.
EP0296123B1 (fr)	1987-06-19	1994-08-31	Sandoz Ag	Peptolides cycliques
EP0373260B1 (fr) *	1987-06-22	1994-03-09	Merck & Co. Inc.	Dérivés de cyclosporine avec un acide aminé modifié en position 8
GB8717300D0 (en)	1987-07-22	1987-08-26	Nat Res Dev	Cyclosporins
GB8717299D0 (en)	1987-07-22	1987-08-26	Nat Res Dev	Peptides
US5227467A (en)	1987-08-03	1993-07-13	Merck & Co., Inc.	Immunosuppressive fluorinated cyclosporin analogs
US4963362A (en)	1987-08-07	1990-10-16	Regents Of The University Of Minnesota	Freeze-dried liposome mixture containing cyclosporin
WO1989001772A1 (fr)	1987-09-03	1989-03-09	University Of Georgia Research Foundation, Inc.	Composition de cyclosporine oculaire
US4839342A (en)	1987-09-03	1989-06-13	University Of Georgia Research Foundation, Inc.	Method of increasing tear production by topical administration of cyclosporin
US5089390A (en)	1987-09-04	1992-02-18	Syntex (U.S.A.) Inc.	2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
US4914188A (en)	1987-11-16	1990-04-03	Merck & Co., Inc.	Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
US5236899A (en)	1987-11-16	1993-08-17	Merck & Co., Inc.	6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US5013719A (en)	1988-05-13	1991-05-07	Merrell Dow Pharmaceuticals Inc.	Method of effecting immunosuppression
US5342625A (en)	1988-09-16	1994-08-30	Sandoz Ltd.	Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko)	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
WO1990006763A1 (fr)	1988-12-05	1990-06-28	The Trustees Of Columbia University In The City Of New York	Nouveaux derives de cyclosporine a, leurs anticorps et leurs utilisations
US4996193A (en)	1989-03-03	1991-02-26	The Regents Of The University Of California	Combined topical and systemic method of administration of cyclosporine
US5540931A (en)	1989-03-03	1996-07-30	Charles W. Hewitt	Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5284826A (en)	1989-07-24	1994-02-08	Sandoz Ltd.	0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5122511A (en)	1990-02-27	1992-06-16	Merck & Co., Inc.	Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5214130A (en)	1990-02-27	1993-05-25	Merck & Co., Inc.	Synthesis of novel immunosuppressive cyclosporin analogs with modified amino acids at position-8
DK0473961T3 (da)	1990-08-15	1996-07-01	Abbott Lab	Immunoassay-reagenser og fremgangsmåde til bestemmelse af cyklosporin
DE69124459T3 (de)	1990-11-02	2001-05-31	Novartis Ag, Basel	Zyklosporine
US5115859A (en)	1990-12-21	1992-05-26	United Technologies Corporation	Regenerable non-venting cooler for protective suit
ATE127528T1 (de)	1991-04-06	1995-09-15	Dresden Arzneimittel	Verfahren zur fermentativen herstellung und isolierung von cyclosporin a sowie neue cyclosporin- bildende stämme.
GB9204466D0 (en)	1992-03-02	1992-04-15	Sandoz Ltd	Improvements in or relating to organic compounds
HU213553B (en)	1992-05-25	1997-07-28	Biogal Gyogyszergyar	Process for isolating of cyclosporin-a
FI92334C (fi)	1992-12-30	1994-10-25	Leiras Oy	Menetelmä syklosporiinien tuottamiseksi ja menetelmässä käytettävä uusi Tolypocladium-kanta
CA2161149A1 (fr)	1993-05-04	1994-11-10	James M. Balkovec	Ether-oxydes de cyclohexapeptidyle et d'aminoalkyle
WO1995026325A2 (fr) *	1994-03-25	1995-10-05	Isotechnika Inc.	Potentialisation de medicaments par deuteration_______________
US5639852A (en)	1994-09-01	1997-06-17	Wisconsin Alumni Research Foundation	Immunostimulatory agents
US5616595A (en)	1995-06-07	1997-04-01	Abbott Laboratories	Process for recovering water insoluble compounds from a fermentation broth
US5624902A (en)	1995-06-07	1997-04-29	Torrey Pines Institute For Molecular Studies	Peptide inhibitors of calmodulin
US5747330A (en)	1996-06-05	1998-05-05	Poli Industria Chimica	Antibiotic producing microbe
US5709797A (en)	1996-06-05	1998-01-20	Poli Industria Chimica S.P.A.	Method of isolating cyclosporins

1998
- 1998-10-08 JP JP2000514928A patent/JP4261049B2/ja not_active Expired - Lifetime
- 1998-10-08 DE DE69840586T patent/DE69840586D1/de not_active Expired - Fee Related
- 1998-10-08 NZ NZ502362A patent/NZ502362A/en not_active IP Right Cessation
- 1998-10-08 CA CA002298572A patent/CA2298572C/fr not_active Expired - Lifetime
- 1998-10-08 AT AT98947718T patent/ATE314388T1/de active
- 1998-10-08 WO PCT/IB1998/001693 patent/WO1999018120A1/fr not_active Ceased
- 1998-10-08 DK DK98947718T patent/DK0991660T3/da active
- 1998-10-08 ES ES98947718T patent/ES2256959T3/es not_active Expired - Lifetime
- 1998-10-08 BR BR9811716-5A patent/BR9811716A/pt not_active Application Discontinuation
- 1998-10-08 DE DE69832984T patent/DE69832984T2/de not_active Expired - Lifetime
- 1998-10-08 EP EP98947718A patent/EP0991660B8/fr not_active Expired - Lifetime
- 1998-10-08 KR KR1020007003743A patent/KR100585348B1/ko not_active Expired - Fee Related
- 1998-10-08 AU AU94542/98A patent/AU750245B2/en not_active Expired
- 1998-10-08 AT AT05024216T patent/ATE423130T1/de not_active IP Right Cessation
2000
- 2000-02-29 NO NO20001020A patent/NO324042B1/no not_active IP Right Cessation
- 2000-08-07 US US09/634,945 patent/US6613739B1/en not_active Expired - Lifetime
- 2000-08-14 US US09/639,708 patent/US6605593B1/en not_active Expired - Lifetime
2001
- 2001-11-07 US US09/985,997 patent/US20020132763A1/en not_active Abandoned
2003
- 2003-10-17 JP JP2003358524A patent/JP2004143168A/ja not_active Withdrawn
2005
- 2005-08-11 JP JP2005233674A patent/JP2005343904A/ja not_active Withdrawn
2007
- 2007-01-26 JP JP2007017196A patent/JP2007119489A/ja not_active Withdrawn
2008
- 2008-05-27 JP JP2008138790A patent/JP2008222725A/ja not_active Withdrawn
- 2008-05-27 JP JP2008138789A patent/JP2008222724A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
US6605593B1 (en)	2003-08-12
JP2007119489A (ja)	2007-05-17
HK1026432A1 (en)	2000-12-15
WO1999018120A1 (fr)	1999-04-15
NO20001020D0 (no)	2000-02-29
AU750245B2 (en)	2002-07-11
CA2298572C (fr)	2002-04-09
DE69832984T2 (de)	2006-09-21
EP0991660A1 (fr)	2000-04-12
NO324042B1 (no)	2007-07-30
US20020132763A1 (en)	2002-09-19
ATE423130T1 (de)	2009-03-15
KR20010030978A (ko)	2001-04-16
JP2008222724A (ja)	2008-09-25
ATE314388T1 (de)	2006-01-15
JP2005343904A (ja)	2005-12-15
JP2001519355A (ja)	2001-10-23
EP0991660B8 (fr)	2006-04-05
US6613739B1 (en)	2003-09-02
DE69840586D1 (de)	2009-04-02
DE69832984D1 (de)	2006-02-02
ES2256959T3 (es)	2006-07-16
BR9811716A (pt)	2000-07-18
NO20001020L (no)	2000-02-29
AU9454298A (en)	1999-04-27
JP4261049B2 (ja)	2009-04-30
KR100585348B1 (ko)	2006-06-01
JP2004143168A (ja)	2004-05-20
NZ502362A (en)	2001-05-25
CA2298572A1 (fr)	1999-04-15
JP2008222725A (ja)	2008-09-25
EP0991660B1 (fr)	2005-12-28

Publication	Publication Date	Title
DK0991660T3 (da)	2006-02-13	Deuterede og udeuterede cyclosporinanaloger og deres anvendelse som immunmodulerende midler
Kruger et al.	1999	Electron capture dissociation of multiply charged peptide cations
Kenny et al.	1992	Fragmentation studies of peptides: the formation of y ions
AU9315398A (en)	1999-03-29	Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
WO2003031464A3 (fr)	2006-03-02	Remodelage et glycoconjugaison de peptides
HUP0002381A1 (hu)	2000-10-28	Apolipoprotein A-1 agonista hatású peptidszármazékok, ezek lipidekkel alkotott komplexei, valamint ezeket tartalmazó gyógyászati készítmények
DE69912952D1 (en)	2003-12-24	Cyclosporine
EP2338333A3 (fr)	2011-07-27	Méthode de glycopegylation et proteines/peptides produits au moyen de ces méthodes
IL128829A0 (en)	2000-01-31	Improved solid-phase peptide and agent for use in such synthesis
ID21956A (id)	1999-08-19	Asam n-(aril dan atau heteroarilasetil) amino ester, komposisi farmasi yang mengandungnya, dan metoda untuk menghambat pelepasan betha-amiloid peptida dan atau sintesanya dengan menggunakan senyawa tersebut
WO1996034107A3 (fr)	1997-04-24	Proteines antivirales, sequences d'adn codant pour ces proteines et utilisations
DK0720482T3 (da)	2004-06-21	Prosaposin og cytokin-afledte peptider som terapeutiske midler
NO961075D0 (no)	1996-03-15	Krystallinsk, vannfritt mykofenolatmofetil og intravenöst preparat derav
WO1995011309A3 (fr)	1995-06-08	Nouvelle phosphoproteine nucleaire mitotique appelee mitosine
ATE330968T1 (de)	2006-07-15	Cyclosporin-derivate und verfahren zu deren herstellung
EP0174279A3 (fr)	1989-01-25	Thérapie de la cyclosporine
NO995481L (no)	1999-11-09	Glykokonjugater av 20 (S)-camptothecin
BR0312889A (pt)	2005-06-14	Polipeptìdeo t20 peguilado
WO2000058456A3 (fr)	2001-02-15	Compositions et methodes permettant de modifier les effets toxiques de composes proteiques
WO2004091475A3 (fr)	2007-04-19	Medicaments pour la maladie de gaucher et procedes d'identification de ces medicaments
WO1996028468A3 (fr)	1997-04-17	Peptides amphiphiles et analogues desdits peptides
AU6415994A (en)	1994-10-24	Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
NO20000519L (no)	2000-03-31	2-acylaminopropanaminer som takykininreseptorantagonister
IT1319674B1 (it)	2003-10-23	Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
CA2511888A1 (fr)	1999-04-15	Analogues de cyclosporine deuteres et leur utilisation comme immunomodulateurs